AG014699

What AG014699 Means in Everyday Medical Language

AG014699 is a medicine also known by the names rucaparib and Rubraca. It belongs to a group of drugs called PARP inhibitors. These drugs work by blocking an enzyme called PARP-1, which helps cells repair damage to their DNA. Cancer cells often rely on this repair process to survive and grow, especially if they have certain genetic mutations. By stopping this repair, AG014699 can help kill cancer cells or slow their growth.

Why AG014699 Can Matter in Cancer Care

This drug is important because it offers a targeted way to treat some cancers, mainly certain prostate and ovarian cancers. It is especially useful when the cancer has specific genetic changes, such as mutations in the BRCA1 or BRCA2 genes. These mutations affect how cancer cells fix their DNA, making them more vulnerable to PARP inhibitors like AG014699. The drug may be used after chemotherapy or hormone therapy, sometimes as maintenance treatment to help keep cancer from growing again.

What Patients Might See or Hear About AG014699

Patients may come across the names AG014699, rucaparib, or Rubraca in their treatment plans, during discussions about genetic testing results, or when exploring clinical trial options. These different names all refer to the same medicine. It might appear in medical reports, drug labels, or conversations with the healthcare team. Understanding that these names mean the same drug can help avoid confusion.

Where AG014699 Might Appear in Cancer Care

The term AG014699 can show up in various places such as treatment plans, genetic test results, clinical trial information, or drug information sheets. It is often mentioned when doctors discuss targeted therapies based on the cancer’s biology. Seeing this term usually means the healthcare team is considering or using a treatment that blocks DNA repair in cancer cells.

What AG014699 Does Not Automatically Mean

Hearing about AG014699 does not mean every patient will receive this drug or that it will work for all cancers. Its use depends on specific factors like genetic mutations, previous treatments, and overall health. It is not a cure but a treatment option that may help control cancer growth. Also, while it is being studied for other cancers, it is approved mainly for certain prostate and ovarian cancers.

How Doctors Use AG014699 in Treatment Planning

Doctors may order genetic tests to see if a patient’s cancer has mutations that make AG014699 more likely to work. This helps personalize treatment choices. The drug is often used after other treatments like chemotherapy or hormone therapy, especially if the cancer has returned or is not responding to standard therapies. It is part of a broader approach called targeted therapy, which aims to attack specific weaknesses in cancer cells.

Common Sources of Confusion and Questions to Ask

Because AG014699 has several names—rucaparib, Rubraca, and PARP-1 inhibitor AG014699—patients and caregivers might find it confusing. It’s helpful to ask your care team how this drug fits into your treatment plan, what side effects to expect, and whether genetic tests can show if it will work for you. Also, ask if the drug is approved for your cancer type or if it is part of a clinical trial. Understanding these details can help you feel more involved in your care.

Safety and Next Steps

This information about AG014699 is educational and does not replace personalized medical advice. Each patient’s situation is unique, so treatment decisions should always be made together with your healthcare provider. If you see the term AG014699 in your medical records or hear it mentioned, the best next step is to talk openly with your cancer care team. They can explain whether this drug is relevant for you, what benefits and risks it may have, and how it fits with other treatments you might receive. Staying informed and asking questions helps you take an active role in your care and understand your options.